Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adults

Table 2 Changes in CSF biomarkers by age and gender and interactive effects predicted from regression models

			p value for interaction term^a
	Age difference^b	Gender difference ^c	Age × gender	Age × gender × ε4
Aβ₄₂ (pg/ml)	37 (–2, 76), 0.09	–5 (–32, 23), 0.75	0.51	0.047
Total tau (pg/ml)	8.9 (4.7, 13.1), <0.01	2.7 (–0.3, 5.7), 0.08	0.43	0.21
p-tau₁₈₁ (pg/ml)	8.5 (5.4, 11.6), <0.01	1.6 (–0.6, 3.8), 0.15	0.85	0.16
E-selectin (pg/ml)^d	13 (–6, 43), 0.47	20 (10, 33), <0.01	0.04	0.65
VCAM1 (ng/dl)	66 (30, 102), <0. 01	24 (8, 39), <0.01	0.34	0.64

Aβ₄₂ amyloid beta_1–42, APOE apolipoprotein E, CSF cerebrospinal fluid, p-tau ₁₈₁ phospho-tau-181, VCAM1 vascular cell adhesion protein 1
^aFrom linear regression models of CSF biomarker on age × gender interaction adjusted for APOE-ε4 status or on age × gender × APOE-ε4 status interaction
^bAge difference: mean difference (95% confidence interval) and p value in CSF Aβ₄₂, total tau, and p-tau₁₈₁ for an increase in participant age from 25 to 75 years; and mean difference and p value in E-selectin and VCAM1 for an increase in participant age from 50 to 75 years
^cGender difference: mean difference (95% confidence interval) and p value in concentration of CSF biomarker in males minus females
^dHypothesis testing carried out on log E-selectin, with results presented back-transformed into the original scale

ISSN: 1758-9193